<span id="midArticle_start"/><span id="midArticle_0"/>Orexigen Therapeutics Inc and partnerTakeda Pharmaceutical Co Ltd said they had filed alawsuit against Actavis Plc to block a generic versionof diet-pill Contrave.
<span id="midArticle_1"/>The lawsuit, filed at a Delaware district court, allegesthat Actavis has infringed patents on Orexigen and Takeda'sweight-loss treatment.
<span id="midArticle_2"/>Contrave is one of the three weight-loss pills that wereexpected to gain quick ground in the market to reduce bodyweight in obese patients.
<span id="midArticle_3"/> <span class="first-article-divide"/>The other two treatments recently approved for weight lossare Arena Pharmaceuticals Inc's Belviq and Vivus Inc's Qsymia.
<span id="midArticle_4"/> <span class="second-article-divide"/>Contrave has been in trouble since March, when anunauthorized release of early data from a study looking intorisks of developing heart problems on taking the drug promptedthe company to abandon the study.
<span id="midArticle_5"/>Takeda, which co-developed the drug and is responsible forselling it in the United States, launched a formal dispute inMay, asking Orexigen to pay the entire cost of a new heart riskstudy.
<span id="midArticle_6"/> <span class="third-article-divide"/>The United States is among the top five countries with thehighest population of obese people, according to the WorldHealth Organization. More than 600 million people were obeseworldwide as of 2014.
<span id="midArticle_7"/>Actavis and Teva Pharmaceutical Industries Ltd have already filed for marketing approval of Qsymia's copy catversion.
<span id="midArticle_8"/>
<span id="midArticle_1"/>The lawsuit, filed at a Delaware district court, allegesthat Actavis has infringed patents on Orexigen and Takeda'sweight-loss treatment.
<span id="midArticle_2"/>Contrave is one of the three weight-loss pills that wereexpected to gain quick ground in the market to reduce bodyweight in obese patients.
<span id="midArticle_3"/> <span class="first-article-divide"/>The other two treatments recently approved for weight lossare Arena Pharmaceuticals Inc's Belviq and Vivus Inc's Qsymia.
<span id="midArticle_4"/> <span class="second-article-divide"/>Contrave has been in trouble since March, when anunauthorized release of early data from a study looking intorisks of developing heart problems on taking the drug promptedthe company to abandon the study.
<span id="midArticle_5"/>Takeda, which co-developed the drug and is responsible forselling it in the United States, launched a formal dispute inMay, asking Orexigen to pay the entire cost of a new heart riskstudy.
<span id="midArticle_6"/> <span class="third-article-divide"/>The United States is among the top five countries with thehighest population of obese people, according to the WorldHealth Organization. More than 600 million people were obeseworldwide as of 2014.
<span id="midArticle_7"/>Actavis and Teva Pharmaceutical Industries Ltd have already filed for marketing approval of Qsymia's copy catversion.
<span id="midArticle_8"/>
via Smart Health Shop Forum http://ift.tt/1ASRdpc
No comments:
Post a Comment